Horizon Kinetics Medical ETF
Horizon Kinetics Medical ETF reported 30 holdings worth US$19.1M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 26, 2026
Horizon Kinetics Medical ETF reported 30 holdings worth US$19.1M as of Jun 30, 2026. Largest: Eli Lilly And Company, Abbvie Inc. and Novartis Ag. Filed Aug 26, 2026 (Form N-PORT).
- Holdings
- 30
- Value as reported
- US$19.1M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 2,936 | US$3.52M | 18.5% |
| Abbvie Inc. | 6,712 | US$1.69M | 8.9% |
| Novartis Ag | 8,406 | US$1.31M | 6.9% |
| Johnson & Johnson | 4,200 | US$1.07M | 5.6% |
| Alkermes Plc | 20,132 | US$1.05M | 5.5% |
| Astrazeneca Plc | 5,015 | US$951K | 5.0% |
| Ionis Pharmaceuticals, Inc. | 10,904 | US$865K | 4.5% |
| Bristol-myers Squibb Company | 14,644 | US$844K | 4.4% |
| Merck & Company, Inc. | 5,872 | US$755K | 4.0% |
| Amgen Inc. | 2,062 | US$747K | 3.9% |
| Alnylam Pharmaceuticals, Inc. | 2,168 | US$653K | 3.4% |
| Biogen Inc. | 2,726 | US$589K | 3.1% |
| Pfizer, Inc. | 22,648 | US$545K | 2.9% |
| Gsk Plc | 19,572 | US$516K | 2.7% |
| Crispr Therapeutics Ag | 9,228 | US$503K | 2.6% |
| Regeneron Pharmaceuticals, Inc. | 630 | US$393K | 2.1% |
| Beam Therapeutics Inc. | 8,388 | US$288K | 1.5% |
| Galectin Therapeutics Inc. | 46,968 | US$218K | 1.1% |
| Intellia Therapeutics, Inc. | 12,584 | US$213K | 1.1% |
| Sandoz Group Ltd | 1,681 | US$152K | 0.80% |
| Replimune Group, Inc. | 12,584 | US$139K | 0.73% |
| Vanda Pharmaceuticals Inc. | 22,648 | US$139K | 0.73% |
| Haleon Plc | 24,888 | US$115K | 0.60% |
| Lantern Pharma Inc. | 25,164 | US$105K | 0.55% |
| Editas Medicine, Inc. | 27,680 | US$89,683 | 0.47% |
| Ge Healthcare Technologies Inc. | 840 | US$53,768 | 0.28% |
| Viatris Inc. | 3,122 | US$49,577 | 0.26% |
| Allogene Therapeutics, Inc. | 16,776 | US$34,894 | 0.18% |
| Pacific Biosciences Of California, Inc. | 10,068 | US$16,914 | 0.09% |
| Decoy Therapeutics Inc. | 21 | US$149 | <0.01% |
Source
View original at SEC
Related